Congratulations Mesoblast on reaching your primary endpoint in CHF trial. Looking at the data there were less events requiring hospitalisation for the control group due to the participants dying! Fantastic result SAID NO ONE EVER!
good luck to long term SHs who actually understand the company they have invested in. My medical knowledge extends to bandaids & paracetamol but my knowledge of number helps me understanf that 60% reduction in mortality is waaaaay superior to current best standard of care! And the fact that Rexlemestocel-L is an add-on to care, just makes the commercialisation deal even sweeter!
HODL!
Congratulations Mesoblast on reaching your primary endpoint in...
-
- There are more pages in this discussion • 855 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
0.045(4.00%) |
Mkt cap ! $1.335B | |||
| Open | High | Low | Value | Volume |
| $1.13 | $1.18 | $1.13 | $4.980M | 4.315M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 73090 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 27903 | 1 |
View Market Depth
| Last trade - 16.10pm 30/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |